FDA is examining the feasibility of requiring abuse-deterrence as a criterion for approving opioids or other abusable drugs.
“As we gain experience with both laboratory and real-world data concerning new opioid products formulated to deter abuse, we are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?